About: Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports
Creator	Abagyan, Ruben Cohen, Isaac Issa, Masara Makunts, Tigran Moumedjian, Talar
Source	MedRxiv
abstract	Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to the risk of drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.19.20107227
has license	medrxiv
sha1sum (hex)	6b4ed1056a6878e0a84fb0bde7b686b15cf210fd
schema:url	https://doi.org/10.1101/2020.05.19.20107227
resource representing a document's title	Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports
resource representing a document's body	covid:6b4ed1056a6878e0a84fb0bde7b686b15cf210fd#body_text
is schema:about of	named entity 'Food' named entity 'rheumatoid arthritis' named entity 'heart' named entity 'malaria' named entity 'COMPLICATIONS' named entity 'RELATED' named entity 'CONFOUNDING FACTORS' named entity 'RISK OF' named entity 'USED' named entity 'COVID-19' named entity 'CHLOROQUINE' named entity 'UNITED STATES FOOD AND DRUG ADMINISTRATION' named entity 'NSAID' named entity 'COADMINISTRATION' named entity 'ASSOCIATED WITH' named entity 'CURRENTLY' named entity 'HEART' named entity 'IDENTIFIED' named entity 'ADVANCED AGE' named entity 'INCLUDING' named entity 'THERAPEUTIC' named entity 'FINDINGS' named entity 'CLINICAL TRIALS' named entity 'CARDIAC COMPLICATIONS' named entity 'DRUGS' named entity 'INCREASED MORTALITY' named entity 'data set' named entity 'cardiovascular' named entity 'China' named entity 'hydroxychloroquine' named entity 'CC-BY-ND' named entity 'HCQ' named entity 'preprint' named entity 'preprint' named entity 'neuropsychiatric' named entity 'NSAIDs' named entity 'AEs' named entity 'odds ratio' named entity 'cohort study' named entity 'Aspirin' named entity 'SLE' named entity 'HCQ' named entity 'quantify' named entity 'sex' named entity 'risk' named entity 'NSAID' named entity 'SARS-CoV-2' named entity 'infection' named entity 'HCQ' named entity 'HCQ' named entity 'first-line treatment' named entity 'SARS-CoV-2' named entity 'inflammatory response' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'COVID' named entity 'CC-BY-ND' named entity 'cardiovascular' named entity 'preprint' named entity 'preprint' named entity 'cardiac complications' named entity 'AEs' named entity 'CC-BY-ND' named entity 'CVD' named entity 'infection' named entity 'prophylaxis' named entity 'systematic review' named entity 'AERS' named entity 'cardiac complications' named entity 'NSAIDs' named entity 'SLE' named entity 'cardiac diseases' named entity 'United States' named entity 'hydroxychloroquine' named entity 'lupus' named entity 'drug' named entity 'drug safety' named entity 'hydroxychloroquine' named entity 'adverse event' named entity 'HCQ' named entity 'World Health Organization' named entity 'higher risk'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software